MarketCap
Facebook
X
Telegram
Exact Sciences Corporation Revenue | EXAS
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Exact Sciences Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.25 B | 2.76 B | 2.5 B | 2.08 B | 1.77 B | 1.49 B | 876 M | 454 M | 266 M | 99.4 M | 39.4 M | 1.8 M | 4.14 M | 4.14 M | 4.16 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.25 B | 1.8 M | 1.04 B |
Quarterly Revenue Exact Sciences Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 851 M | 811 M | 707 M | - | 709 M | 699 M | 638 M | - | 628 M | 622 M | 602 M | - | 523 M | 522 M | 487 M | 474 M | 456 M | 435 M | 402 M | 466 M | 408 M | 269 M | 348 M | 296 M | 219 M | 200 M | 162 M | 143 M | 118 M | 103 M | 90.3 M | 87.4 M | 72.6 M | 57.6 M | 48.4 M | - | - | - | - | - | 12.6 M | 8.12 M | 4.27 M | - | 294 K | 294 K | 294 K | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M | 1.04 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 851 M | 294 K | 254 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Neogen Corporation
NEOG
|
895 M | $ 9.4 | 2.29 % | $ 2.04 B | USA |
 |
Natera
NTRA
|
2.31 B | $ 253.82 | 0.63 % | $ 34.7 B | USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
343 K | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
11.7 M | - | -61.36 % | $ 2.46 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
17.8 B | $ 26.1 | 2.19 % | $ 24.7 B |  Niderland |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Personalis
PSNL
|
69.6 M | $ 11.73 | -1.26 % | $ 1.05 B | USA |
 |
Quidel Corporation
QDEL
|
1.66 B | $ 16.5 | -1.02 % | $ 695 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
Co-Diagnostics
CODX
|
622 K | $ 1.51 | 7.09 % | $ 2.01 M | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
7.66 M | - | - | $ 7.1 B |  Australia |
 |
Neuronetics
STIM
|
149 M | $ 1.82 | -2.67 % | $ 120 M | USA |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
380 M | $ 35.41 | -0.95 % | $ 1.89 B | USA |
 |
NeoGenomics
NEO
|
727 M | $ 15.27 | 13.96 % | $ 1.96 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
190 M | - | - | $ 2.69 B | USA |
 |
Waters Corporation
WAT
|
932 M | $ 379.48 | -1.15 % | $ 22.6 B | USA |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 584.93 | 2.44 % | $ 16.9 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
11 B | $ 235.22 | -0.31 % | $ 26.1 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K |  Israel |
 |
Exagen
XGN
|
66.6 M | $ 4.35 | -2.25 % | $ 93.8 M | USA |
 |
Biomerica
BMRA
|
5.31 M | $ 1.59 | -0.62 % | $ 3.65 M | USA |
 |
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | USA |
 |
Organovo Holdings
ONVO
|
131 K | - | -2.3 % | $ 19.4 M | USA |
 |
DarioHealth Corp.
DRIO
|
22.4 M | $ 7.1 | -5.27 % | $ 28.3 M | Israel |
 |
OpGen
OPGN
|
30.2 M | - | -16.95 % | $ 1.54 M | USA |
 |
Anixa Biosciences
ANIX
|
210 K | $ 3.48 | -1.14 % | $ 113 K | USA |
 |
PerkinElmer
PKI
|
2.86 B | - | -0.91 % | $ 14.7 B | USA |
 |
DexCom
DXCM
|
4.66 B | $ 75.14 | 0.39 % | $ 29.3 B | USA |
 |
OPKO Health
OPK
|
148 M | $ 1.37 | -17.27 % | $ 1.03 B | USA |
 |
Psychemedics Corporation
PMD
|
19.7 M | - | -1.84 % | $ 15.3 M | USA |
 |
ICON Public Limited Company
ICLR
|
8.25 B | $ 178.18 | -1.14 % | $ 14 B |  Irlanda |
 |
Quotient Limited
QTNT
|
38.5 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
T2 Biosystems
TTOO
|
7.19 M | - | -39.35 % | $ 313 K | USA |
 |
Renalytix AI plc
RNLX
|
2.29 M | - | 5.66 % | $ 22.7 M | Britain |
 |
Syneos Health
SYNH
|
5.39 B | - | - | $ 4.46 B | USA |